A First-In-Human Phase I Study of sEphB4-HSA in Patients with Advanced Solid Tumors with Expansion at the Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs SEphB4-HSA (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- 18 Apr 2017 Planned End Date changed from 1 Jan 2017 to 6 Sep 2019.
- 18 Apr 2017 Planned primary completion date changed from 1 Jan 2016 to 6 Sep 2018.
- 02 Dec 2016 Interim results (n=70) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History